


Methylnaltrexone bromide

Chemical Properties

CAS No. :	73232-52-7
Formula:	C ₂₁ H ₂₆ BrNO ₄
Molecular Weight:	436.35
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



Biological Description

Description	Methylnaltrexone bromide (MOA-728) is one of the newer agents of peripherally-acting μ -opioid antagonists. Methylnaltrexone bromide acts to reverse some of the side effects of opioid drugs such as constipation without affecting analgesia or precipitating withdrawals.
Targets(IC50)	Opioid Receptor

Solubility Information

Solubility	H ₂ O: Insoluble, DMSO: 70.71 mg/mL (162.05 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 7.07 mg/mL (16.2 mM),Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2917 mL	11.4587 mL	22.9174 mL
5 mM	0.4583 mL	2.2917 mL	4.5835 mL
10 mM	0.2292 mL	1.1459 mL	2.2917 mL
50 mM	0.0458 mL	0.2292 mL	0.4583 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Rauck RL. Treatment of opioid-induced constipation: focus on the peripheral μ -opioid receptor antagonist methylnaltrexone. *Drugs*. 2013 Aug;73(12):1297-306. doi: 10.1007/s40265-013-0084-5. Review. PubMed PMID: 23881667.
- Liu X, Yang J, Yang C, et al. Morphine promotes the malignant biological behavior of non-small cell lung cancer cells through the MOR/Src/mTOR pathway. *Cancer Cell International*. 2021, 21(1): 1-14
- Liu X, Yang J, Yang C, et al. Morphine promotes the malignant biological behavior of non-small cell lung cancer cells through the MOR/Src/mTOR pathway. *Cancer Cell International*. 2021, 21(1): 1-14
- Grover M, Camilleri M. Treatment with Methylnaltrexone and IVIG for Paraneoplastic Gastrointestinal Dysmotility. *Gastroenterol Hepatol (N Y)*. 2013 Jan;9(1):51-3. Review. PubMed PMID: 24707236; PubMed Central PMCID: PMC3975980.
- Gu F, Zhou Y, Tian L, et al. Morphine promotes non-small cell lung cancer progression by downregulating E-cadherin via the PI3K/AKT/mTOR pathway. *Scientific Reports*. 2024, 14(1): 21130.
- Bader S, Dürk T, Becker G. Methylnaltrexone for the treatment of opioid-induced constipation. *Expert Rev Gastroenterol Hepatol*. 2013 Jan;7(1):13-26. doi: 10.1586/egh.12.63. Review. PubMed PMID: 23265145.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481